Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

cbdMD

AMEX:YCBD
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YCBD
AMEX
$43M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

cbdMD, Inc. produces and distributes various cannibidiol (CBD) products. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • cbdMD has significant price volatility in the past 3 months.
YCBD Share Price and Events
7 Day Returns
4.5%
AMEX:YCBD
6.2%
US Pharmaceuticals
8%
US Market
1 Year Returns
-79.6%
AMEX:YCBD
0.7%
US Pharmaceuticals
-8.1%
US Market
YCBD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
cbdMD (YCBD) 4.5% 3% -24.5% -79.6% - -
US Pharmaceuticals 6.2% -0.1% -7% 0.7% 12.3% 7.3%
US Market 8% -4.5% -17.8% -8.1% 13.2% 23.7%
1 Year Return vs Industry and Market
  • YCBD underperformed the Pharmaceuticals industry which returned 0.7% over the past year.
  • YCBD underperformed the Market in United States of America which returned -8.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

YCBD Value

 Is cbdMD undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of cbdMD to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for cbdMD.

AMEX:YCBD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AMEX:YCBD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.647 (1 + (1- 21%) (19.37%))
0.83
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.83 * 5.44%)
6.25%

Discounted Cash Flow Calculation for AMEX:YCBD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for cbdMD is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

AMEX:YCBD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.25%)
2020 -11.00 Analyst x1 -10.35
2021 8.00 Analyst x1 7.09
2022 20.00 Analyst x1 16.67
2023 29.00 Analyst x1 22.75
2024 34.00 Analyst x1 25.10
2025 37.65 Est @ 10.72% 26.16
2026 40.67 Est @ 8.03% 26.60
2027 43.17 Est @ 6.14% 26.57
2028 45.25 Est @ 4.82% 26.21
2029 47.01 Est @ 3.9% 25.63
Present value of next 10 years cash flows $192.00
AMEX:YCBD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $47.01 × (1 + 1.74%) ÷ (6.25% – 1.74%)
$1,059.43
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,059.43 ÷ (1 + 6.25%)10
$577.56
AMEX:YCBD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $192.00 + $577.56
$769.56
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $769.56 / 51.34
$14.99
AMEX:YCBD Discount to Share Price
Calculation Result
Value per share (USD) From above. $14.99
Current discount Discount to share price of $0.85
= -1 x ($0.85 - $14.99) / $14.99
94.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price cbdMD is available for.
Intrinsic value
>50%
Share price is $0.85 vs Future cash flow value of $14.99
Current Discount Checks
For cbdMD to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • cbdMD's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • cbdMD's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for cbdMD's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are cbdMD's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:YCBD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.42
AMEX:YCBD Share Price ** AMEX (2020-04-08) in USD $0.85
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.76x
United States of America Market PE Ratio Median Figure of 2,949 Publicly-Listed Companies 13.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of cbdMD.

AMEX:YCBD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:YCBD Share Price ÷ EPS (both in USD)

= 0.85 ÷ -1.42

-0.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • cbdMD is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • cbdMD is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does cbdMD's expected growth come at a high price?
Raw Data
AMEX:YCBD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
47.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.93x
United States of America Market PEG Ratio Median Figure of 2,009 Publicly-Listed Companies 0.9x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for cbdMD, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on cbdMD's assets?
Raw Data
AMEX:YCBD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.00
AMEX:YCBD Share Price * AMEX (2020-04-08) in USD $0.85
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.46x
United States of America Market PB Ratio Median Figure of 5,163 Publicly-Listed Companies 1.29x
AMEX:YCBD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:YCBD Share Price ÷ Book Value per Share (both in USD)

= 0.85 ÷ 2.00

0.42x

* Primary Listing of cbdMD.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • cbdMD is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess cbdMD's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. cbdMD has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

YCBD Future Performance

 How is cbdMD expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is cbdMD expected to grow at an attractive rate?
  • cbdMD's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • cbdMD's earnings growth is expected to exceed the United States of America market average.
  • cbdMD's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
AMEX:YCBD Future Growth Rates Data Sources
Data Point Source Value (per year)
AMEX:YCBD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 47.5%
AMEX:YCBD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 26%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 6.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:YCBD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:YCBD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 156 39 37 1
2023-09-30 144 33 34 1
2022-09-30 118 24 28 1
2021-09-30 106 11 11 3
2020-09-30 56 -10 7 3
2020-04-09
AMEX:YCBD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 33 -19 -32
2019-09-30 24 -15 -45
2019-06-30 8 -10 -63
2019-03-31 3 -6 -35
2018-12-31 0 -5 -2
2018-09-30 0 -6 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • cbdMD's earnings are expected to grow significantly at over 20% yearly.
  • cbdMD's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:YCBD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from cbdMD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:YCBD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30 0.86 0.86 0.86 1.00
2023-09-30 0.80 0.80 0.80 1.00
2022-09-30 0.65 0.65 0.65 1.00
2021-09-30 0.25 0.40 0.10 2.00
2020-09-30 0.21 0.21 0.21 1.00
2020-04-09
AMEX:YCBD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.42
2019-09-30 -2.54
2019-06-30 -4.87
2019-03-31 -3.82
2018-12-31 -0.19
2018-09-30 -0.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if cbdMD will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess cbdMD's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
cbdMD has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

YCBD Past Performance

  How has cbdMD performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare cbdMD's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • cbdMD does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare cbdMD's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare cbdMD's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
cbdMD's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from cbdMD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:YCBD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 33.33 -31.60 39.62
2019-09-30 23.65 -45.43 28.88
2019-06-30 7.68 -62.69 16.48
2019-03-31 2.83 -34.78 6.72
2018-12-31 0.24 -1.59 1.71
2018-09-30 0.46 -1.80 2.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if cbdMD has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if cbdMD has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if cbdMD improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess cbdMD's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
cbdMD has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

YCBD Health

 How is cbdMD's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up cbdMD's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • cbdMD is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • cbdMD's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of cbdMD's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 32.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from cbdMD Company Filings, last reported 3 months ago.

AMEX:YCBD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 55.52 0.46 4.43
2019-09-30 37.60 0.19 5.50
2019-06-30 25.15 0.00 13.68
2019-03-31 -13.42 0.75 7.17
2018-12-31 18.13 0.76 9.91
2018-09-30 14.02 0.00 6.49
  • cbdMD's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if cbdMD's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • cbdMD has less than a year of cash runway based on current free cash flow.
  • cbdMD has less than a year of cash runway if free cash flow continues to grow at historical rates of 116.5% each year.
X
Financial health checks
We assess cbdMD's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. cbdMD has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

YCBD Dividends

 What is cbdMD's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from cbdMD dividends.
If you bought $2,000 of cbdMD shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate cbdMD's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate cbdMD's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:YCBD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1933 Stocks 2.8%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:YCBD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as cbdMD has not reported any payouts.
  • Unable to verify if cbdMD's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of cbdMD's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as cbdMD has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess cbdMD's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can cbdMD afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. cbdMD has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

YCBD Management

 What is the CEO of cbdMD's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Martin Sumichrast
COMPENSATION $504,115
AGE 52
TENURE AS CEO 0.8 years
CEO Bio

Mr. Martin A. Sumichrast serves as Chairman of the Board at cbdMD, Inc. He serves as Co-Chief Executive Officer at cbdMD, Inc. since July 1, 2019 and served as its President since September 2016. He has been a Director at cbdMD, Inc. since April 2015 and was its Chief Executive Officer since September 2016. He serves as Managing Director of Washington Capital, LLC. Mr. Sumichrast served as the Managing Director at Lomond International, Inc. from 2002 to 2013. He founded Global Capital Partners Inc. and served as its Vice Chairman, Chief Financial Officer, Executive Vice President and Secretary. He holds experience in investing and providing business advisory services to corporations in the United States, Europe and Asia. He served as the Chairman, Chief Executive Officer and President of Global Capital Partners Inc. from December 1998 to January 22, 2002. He served as the Chairman and Director of Moneyzone.com, Inc. He is a Co-founder of Siskey Capital, LLC and serves as its Vice Chairman. He serves as a Director of Kure Corp. and Jadeveon Clowney Help-In-Time Foundation. He served as a Director of Global Capital Partners Inc. from its inception in 1993 to January 22, 2002. He served as an Independent Director of Social Reality, Inc. since January 27, 2015 until January 6, 2017. He is employed at Omni Nutraceuticals, Inc. He is a co-author of Opportunities in Finance Careers and The New Complete Book of Homebuying. Mr. Sumichrast holds a Bachelor of Science from the University of Maryland.

CEO Compensation
  • Insufficient data for Martin to compare compensation growth.
  • Martin's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the cbdMD management team in years:

0.8
Average Tenure
57
Average Age
  • The average tenure for the cbdMD management team is less than 2 years, this suggests a new team.
Management Team

Martin Sumichrast

TITLE
Chairman & Co-CEO
COMPENSATION
$504K
AGE
52
TENURE
0.8 yrs

Raymond Coffman

TITLE
Co-Founder
COMPENSATION
$168K
AGE
57
TENURE
0.8 yrs

Caryn Dunayer

TITLE
Co-Founder & President
COMPENSATION
$173K
TENURE
0.8 yrs

Mark Elliott

TITLE
CFO & COO
COMPENSATION
$320K
AGE
58
TENURE
3.5 yrs

John Weston

TITLE
Director of Investor Relations
Board of Directors Tenure

Average tenure and age of the cbdMD board of directors in years:

2.2
Average Tenure
57
Average Age
  • The average tenure for the cbdMD board of directors is less than 3 years, this suggests a new board.
Board of Directors

Martin Sumichrast

TITLE
Chairman & Co-CEO
COMPENSATION
$504K
AGE
52

Raymond Coffman

TITLE
Co-Founder
COMPENSATION
$168K
AGE
57
TENURE
1.3 yrs

Scott Stephen

TITLE
Independent Director
COMPENSATION
$132K
AGE
53
TENURE
1 yrs

Bakari Sellers

TITLE
Independent Director
COMPENSATION
$135K
AGE
34
TENURE
3.1 yrs

Sy Siegel

TITLE
Independent Director
COMPENSATION
$139K
AGE
76
TENURE
3.1 yrs

Billy Raines

TITLE
Independent Director
COMPENSATION
$119K
AGE
59
TENURE
1 yrs

Greg Morris

TITLE
Independent Director
COMPENSATION
$134K
AGE
58
TENURE
3.1 yrs

Peter Ghiloni

TITLE
Independent Director
COMPENSATION
$130K
AGE
68
TENURE
1 yrs

Anthony Shriver

TITLE
Independent Director
COMPENSATION
$131K
AGE
54
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by cbdMD individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
10. Mar 20 Buy Peter Ghiloni Individual 09. Mar 20 09. Mar 20 25,000 $0.75 $18,720
16. Jan 20 Buy Raymond Coffman Individual 14. Jan 20 14. Jan 20 125,000 $1.00 $125,000
25. Feb 20 Buy Mark Elliott Individual 27. Jan 20 27. Jan 20 5,000 $1.06 $5,300
16. Jan 20 Buy Washington Capital, Llc Company 14. Jan 20 14. Jan 20 125,000 $1.00 $125,000
16. Jan 20 Buy Peter Ghiloni Individual 14. Jan 20 14. Jan 20 125,000 $1.00 $125,000
16. Jan 20 Buy William Raines Individual 14. Jan 20 14. Jan 20 20,000 $1.00 $20,000
16. Jan 20 Buy Scott Stephen Individual 14. Jan 20 14. Jan 20 20,000 $1.00 $20,000
16. Jan 20 Buy Gregory Morris Individual 14. Jan 20 14. Jan 20 15,000 $1.00 $15,000
16. Jan 20 Buy Bakari Sellers Individual 14. Jan 20 14. Jan 20 10,000 $1.00 $10,000
16. Jan 20 Buy Mark Elliott Individual 14. Jan 20 14. Jan 20 15,000 $1.00 $15,000
17. Apr 19 Sell EE1 Holdings, LLC Company 16. Apr 19 16. Apr 19 -283,000 $4.00 $-1,132,000
17. Apr 19 Sell Erik Sterling Individual 16. Apr 19 16. Apr 19 -774,667 $4.00 $-3,098,668
X
Management checks
We assess cbdMD's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. cbdMD has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

YCBD News

Simply Wall St News

YCBD Company Info

Description

cbdMD, Inc. produces and distributes various cannibidiol (CBD) products. It owns and operates the consumer hemp-based CBD brand, cbdMD. The company's product categories include CBD tinctures, capsules, gummies, bath bombs, topical creams, and animal treats and oils. It also offers pet related CBD products under the Paw CBD brand name. The company distributes its products through an e-commerce Website, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.

Details
Name: cbdMD, Inc.
YCBD
Exchange: AMEX
Founded: 2015
$43,429,958
51,335,648
Website: http://www.cbdmd.com
Address: cbdMD, Inc.
8845 Red Oak Boulevard,
Charlotte,
North Carolina, 28217,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX YCBD Common Stock NYSE MKT LLC US USD 21. Dec 2018
AMEX YCBD.PRA 8% CNV PFD SR A NYSE MKT LLC US USD 21. Oct 2019
Number of employees
Current staff
Staff numbers
182
cbdMD employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 03:44
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/09
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.